RxDoctor Payments Data

Peter Ririe

Ophthalmology · American Fork, UTNPI 1063856920

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 94.8% of the total across 17 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by Alcon at 42.9% of the total. That places this record below the midpoint for ophthalmology clinicians in UT, where the typical reported total is $987.

$742in general payments, 2019–2025

Across 17 payments — averaging $43.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$318
  • Rxsight Inc$255
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$99
  • Boston Scientific$34
  • Shire North American Group Inc$18
  • AbbVie$17
$118,000in research payments, 2019–2025

Across 13 payments — averaging $9076.92 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Rxsight Inc$118K

What the payments were for

  • Speaking & faculty fees$395%
  • Food & beverage$70395%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$742 in reported general payments places this provider in the 40th percentile of 191 ophthalmology providers in Utah.

See all ophthalmology providers in Utah

Medicare billing

Part B allowed, 2024
$188,444
Medicare patients
622
Services billed
1,375

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost14$8,124
Latanoprost331$4,547
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat149$2,838
Travoprost11$2,726
Prednisolone Acetate79$2,408
Tobramycin-DexamethasoneTobramycin/Dexamethasone58$2,134
Fluorometholone18$1,187
Brimonidine Tartrate32$543
ErythromycinErythromycin Base31$378
Ofloxacin28$300
Timolol Maleate22$125

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan$17$8,12414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 191 ophthalmology providers in Utah.

Other ophthalmology in American Fork

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →